BML Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

BML Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38M	Sell	7,058,657 -431,343	-6%	-$1.98M	24.38%	2
2025 Q4	$26.7M	Buy	7,490,000 +16,037	+0.2%	+$51K	23.11%	2
2025 Q3	$21.7M	Sell	7,473,963 -135,849	-2%	-$464K	19.85%	2
2025 Q2	$27.4M	Hold	7,609,812	–	–	20.73%	1
2025 Q1	$22.8M	Buy	7,609,812 +1,500	+0%	+$4.68K	18.41%	1
2024 Q4	$25.5M	Buy	7,608,312 +958,312	+14%	+$3.18M	15.83%	3
2024 Q3	$22.3M	Buy	6,650,000 +274,379	+4%	+$995K	13.11%	3
2024 Q2	$21.1M	Buy	6,375,621 +838,911	+15%	+$3.13M	15.06%	2
2024 Q1	$22.4M	Buy	5,536,710 +74,631	+1%	+$292K	14.75%	2
2023 Q4	$16.7M	Buy	5,462,079 +662,079	+14%	+$2.01M	12.62%	3
2023 Q3	$14.4M	Buy	4,800,000 +2,563,761	+115%	+$8.72M	13.22%	3
2023 Q2	$8.36M	Buy	+2,236,239	New	+$8.37M	7.52%	4

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BML Capital Management's AVIR Position: Q1 2026 in Review

BML Capital Management reduced its Atea Pharmaceuticals (AVIR) stake by 5.8% in Q1 2026, selling an estimated $1.98M and leaving 7,058,657 shares worth $38M. The position accounts for 24.38% of the portfolio, ranked #2.

BML Capital Management first reported a position in AVIR in Q2 2023 and has held it in 12 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

BML Capital Management held 7,058,657 shares of Atea Pharmaceuticals worth $38M as of Q1 2026.
BML Capital Management sold 431,343 Atea Pharmaceuticals shares in Q1 2026, an estimated $1.98M.
Atea Pharmaceuticals made up 24.38% of BML Capital Management's portfolio in Q1 2026, its #2 holding.
BML Capital Management first reported a position in Atea Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on BML Capital Management's 13F filing for Q1 2026, filed 6 May 2026.